The GORE® TIGRIS® Vascular Stent goes beyond bare metal with advanced technologies to deliver precise placement and conformability in complex anatomies.

  • On target, every time. Single-handed, precise delivery – 100% of stents deployed within the nominal length.1
  • High-flexion conformability. Optimal combination of straightening force and elongation, allowing the artery to bend and move naturally.*
  • Accuracy with minimal elongation. Average elongation < 0.1% in a U.S.Clinical Study.2
  • Long-term fracture resistance. Zero stent frame fractures at 12 and 24 months.1
  • Lasting thromboresistance. Proven CBAS Heparin Surface technology. **
  • Patency in high-flexion applications. 86% freedom from target lesion revascularization (fTLR) at 12 months in a popliteal lesion study.3
* Data on file. Competitive Comparison Study. February 2015
** See full CBAS Heparin Surface references at
† Data on File. Challenging recirculating human blood loop model.
  1. U.S. Food and Drug Administration. Center for Devices and Radiological Health. FDA Summary of Safety and Effectiveness Data. P160004. Published July 27, 2016. Accessed August 10, 2016.
  2. Laird JR. Novel nitinol stent for long lesions in the superficial femoral artery and proximal popliteal artery: 24 month results from the TIGRIS Randomized Trial. Presented at VIVA 2016: Vascular Interventional Advances Conference; September 18-22, 2016; Las Vegas, NV.
  3. Parthipun A, Diamantopoulos A, Kitrou P, et al. Use of a new hybrid heparin-bonded nitinol ring stent in the popliteal artery: procedural and mid-term clinical and anatomical outcomes. Cardiovascular & Interventional Radiology 2015;38(4):846-854.
  4. SUPERA® Peripheral Stent System [Instructions for Use]. Webster, TX: IDEV Technologies, Inc; 2014.

GORE TIGRIS Vascular Stent